These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 16887605)

  • 1. In vitro activity of linezolid and eperezolid, two novel oxazolidinone antimicrobial agents, against anaerobic bacteria.
    Yagi BH; Zurenko GE
    Anaerobe; 1997 Oct; 3(5):301-6. PubMed ID: 16887605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An in vitro time-kill assessment of linezolid and anaerobic bacteria.
    Yagi BH; Zurenko GE
    Anaerobe; 2003 Feb; 9(1):1-3. PubMed ID: 16887680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vitro activities of ABT-773 against 362 clinical isolates of anaerobic bacteria.
    Citron DM; Appleman MD
    Antimicrob Agents Chemother; 2001 Jan; 45(1):345-8. PubMed ID: 11120995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ["In vitro" activity of ten antimicrobial agents against anaerobic bacteria. A collaborative study, 1999-2002].
    Litterio M; Bianchini H; Carloni G; Di Martino A; Fernández Canigia L; Greco G; Legaria C; Rollet R; Rossetti A; Predari SC; Castello L
    Rev Argent Microbiol; 2004; 36(3):130-5. PubMed ID: 15559195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro activity of PH-027 versus linezolid and other anti-anaerobic antimicrobials against clinical isolates of Clostridium difficile and other anaerobic bacteria.
    Phillips OA; Rotimi VO; Jamal WY; Shahin M; Verghese TL
    J Chemother; 2003 Apr; 15(2):113-7. PubMed ID: 12797385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations.
    Jones RN; Ross JE; Fritsche TR; Sader HS
    J Antimicrob Chemother; 2006 Feb; 57(2):279-87. PubMed ID: 16326811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the in vitro activity of NVP-LMB415 against clinical anaerobic isolates with emphasis on the Bacteroides fragilis group.
    Snydman DR; Jacobus NV; McDermott LA
    J Antimicrob Chemother; 2005 Jun; 55(6):1024-8. PubMed ID: 15824092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries.
    Jones RN; Fritsche TR; Sader HS; Ross JE
    Diagn Microbiol Infect Dis; 2007 Oct; 59(2):199-209. PubMed ID: 17908617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activities of daptomycin, vancomycin, and penicillin against Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes.
    Tyrrell KL; Citron DM; Warren YA; Fernandez HT; Merriam CV; Goldstein EJ
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2728-31. PubMed ID: 16870765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci.
    Livermore DM; Mushtaq S; Warner M; Woodford N
    J Antimicrob Chemother; 2009 Apr; 63(4):713-5. PubMed ID: 19164418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.
    Citron DM; Merriam CV; Tyrrell KL; Warren YA; Fernandez H; Goldstein EJ
    Antimicrob Agents Chemother; 2003 Jul; 47(7):2334-8. PubMed ID: 12821492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative in vitro activities of XRP 2868, pristinamycin, quinupristin-dalfopristin, vancomycin, daptomycin, linezolid, clarithromycin, telithromycin, clindamycin, and ampicillin against anaerobic gram-positive species, actinomycetes, and lactobacilli.
    Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell KL; Fernandez HT; Bryskier A
    Antimicrob Agents Chemother; 2005 Jan; 49(1):408-13. PubMed ID: 15616322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries.
    Jones RN; Kohno S; Ono Y; Ross JE; Yanagihara K
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):191-201. PubMed ID: 19500528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro antibacterial activities of a novel oxazolidinone, OCID0050.
    Paul-Satyaseela M; Solanki SS; Sathishkumar D; Bharani T; Magesh V; Rajagopal S
    J Antimicrob Chemother; 2009 Oct; 64(4):797-800. PubMed ID: 19689978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Study of obligate anaerobic bacterial sensitivity to tinidazole and metronidazole (determination of minimal inhibiting concentration--MIC)].
    Kałowski M; Dybicki J; Kedzia A; Lukiański M
    Wiad Lek; 1993 Mar; 46(5-6):211-5. PubMed ID: 8249400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial susceptibility of anaerobic bacteria in New Zealand: 1999-2003.
    Roberts SA; Shore KP; Paviour SD; Holland D; Morris AJ
    J Antimicrob Chemother; 2006 May; 57(5):992-8. PubMed ID: 16507560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006.
    Zhanel GG; DeCorby M; Nichol KA; Wierzbowski A; Baudry PJ; Karlowsky JA; Lagacé-Wiens P; Walkty A; Mulvey MR; Hoban DJ;
    Diagn Microbiol Infect Dis; 2008 Sep; 62(1):67-80. PubMed ID: 18513913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and in vitro antibacterial activity of novel methylamino piperidinyl oxazolidinones.
    Srivastava BK; Soni R; Patel JZ; Solanki M; Valani D; Gupta S; Mishra B; Takale V; Pandya P; Jain MR; Patel PR
    Bioorg Med Chem Lett; 2007 Sep; 17(18):5227-32. PubMed ID: 17624776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of linezolid against clinical isolates of Fusobacterium spp.
    Daeschlein G; Hoehne C; Assadian O; Daxboeck F; Meinl C; Kramer A; Kekulé AS
    J Antimicrob Chemother; 2006 Oct; 58(4):789-93. PubMed ID: 16905529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tinidazole inhibitory and cidal activity against anaerobic periodontal pathogens.
    Alou L; Giménez MJ; Manso F; Sevillano D; Torrico M; González N; Granizo JJ; Bascones A; Prieto J; Maestre JR; Aguilar L
    Int J Antimicrob Agents; 2009 May; 33(5):449-52. PubMed ID: 19097755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.